Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) candidate vaccine to be administered for the first time in humans. The study intervention will be evaluated in European adults in Stage 1 (a 2-step staggered design) followed by African adults in Stage 2.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05480800
Study type Interventional
Source GlaxoSmithKline
Contact US GSK Clinical Trials Call Center
Phone 877-379-3718
Email GSKClinicalSupportHD@gsk.com
Status Recruiting
Phase Phase 1/Phase 2
Start date September 13, 2022
Completion date December 18, 2024

See also
  Status Clinical Trial Phase
Completed NCT02689193 - IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres
Completed NCT01608815 - Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects Phase 3
Completed NCT03073707 - Reservoir of Invasive Salmonellosis in Children, DRC N/A
Recruiting NCT06213506 - A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants Phase 2
Recruiting NCT04694235 - Egg Intervention During Pregnancy in Indonesia N/A
Recruiting NCT05870150 - Challenge Non-Typhoidal Salmonella (CHANTS) Study N/A
Completed NCT00002052 - Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients N/A